Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Alcohol Use Disorder
NCT ID: NCT03829761
Last Updated: 2023-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2019-02-20
2023-09-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cortical rTMS as a Tool to Change Brain Reactivity to Alcohol Cues
NCT02939313
Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration
NCT04971681
Deep Repetitive Transcranial Magnetic Stimulation for Alcohol Use Disorder
NCT02691390
Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder
NCT06415721
A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder
NCT05621538
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cerebellar rTMS
Cerebellar rTMS. 1Hz repetitive transcranial magnetic stimulation (rTMS) to cerebellar vermis.
Repetitive transcranial magnetic stimulation (rTMS)
Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.
Sham TMS
Sham TMS. Sham transcranial magnetic stimulation to cerebellar vermis.
Sham transcranial magnetic stimulation
Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Repetitive transcranial magnetic stimulation (rTMS)
Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.
Sham transcranial magnetic stimulation
Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Interested in cutting down or quitting drinking;
* Able to provide voluntary informed consent;
* Have at least 4 heavy drinking days (≥ 5 drinks per day for men, and ≥4 for women) in the past 60 days;
* Currently receiving treatment for alcohol use disorder.
Exclusion Criteria
* Other urgent medical problems, as determined by the study physician from the history and physical exam;
* Schizophrenia, schizoaffective disorder, bipolar I disorder
* Suicidal thoughts (intent or plan) in the last month;
* Current moderate or severe other SUD (except nicotine or marijuana) or other drug (except nicotine or marijuana) use in the past month;
* Active legal problems with the potential to result in incarceration;
* Pregnancy or lactation, or child bearing age and sexually active but not on birth control (barrier methods allowed);
* Current daily use of anti-craving medications, antidepressants (at doses considered therapeutic for depression), benzodiazepines, antipsychotics (at doses considered therapeutic for psychosis or mood stabilization), mood stabilizers (at doses considered therapeutic for mood stabilization);
* Have previously undergone rTMS (to assure the blind is effective);
* Personal or familial (in first degree relatives) history of epilepsy;
* Any contraindication for Magnetic Resonance Imaging (MRI) or TMS including metal shards or certain implants (pacemakers etc.) in the body.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
The Mind Research Network
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jon Houck
Associate Professor of Translational Neuroscience
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jon M Houck, PhD
Role: PRINCIPAL_INVESTIGATOR
The Mind Research Network
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Mind Research Network
Albuquerque, New Mexico, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14918
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.